Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study.

De Nunzio C, Brassetti A, Simone G, Lombardo R, Mastroianni R, Collura D, Muto G, Gallucci M, Tubaro A.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):438-445. doi: 10.1038/s41391-018-0054-9. Epub 2018 Jun 4. Erratum in: Prostate Cancer Prostatic Dis. 2019 Feb 1;:.

PMID:
29867154
2.

Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study.

De Nunzio C, Simone G, Brassetti A, Mastroianni R, Collura D, Muto G, Gallucci M, Tubaro A.

BMC Cancer. 2016 Jul 7;16:407. doi: 10.1186/s12885-016-2442-7.

3.

Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.

Gao Y, Jiang CY, Mao SK, Cui D, Hao KY, Zhao W, Jiang Q, Ruan Y, Xia SJ, Han BM.

Asian J Androl. 2016 Jul-Aug;18(4):639-43. doi: 10.4103/1008-682X.169984.

4.

Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics.

Jalloh M, Myers F, Cowan JE, Carroll PR, Cooperberg MR.

Eur Urol. 2015 Mar;67(3):451-7. doi: 10.1016/j.eururo.2014.03.026. Epub 2014 Apr 5.

5.

Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy.

Morlacco A, Dal Moro F, Rangel LJ, Carlson RE, Schulte PJ, Jeffrey KR.

Urol Oncol. 2018 Dec;36(12):528.e1-528.e6. doi: 10.1016/j.urolonc.2018.10.003. Epub 2018 Nov 13.

PMID:
30446466
6.

Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.

Lebdai S, Mathieu R, Leger J, Haillot O, Vincendeau S, Rioux-Leclercq N, Fournier G, Perrouin-Verbe MA, Doucet L, Azzouzi AR, Rigaud J, Renaudin K, Charles T, Bruyere F, Fromont G.

Urol Oncol. 2018 Feb;36(2):80.e17-80.e24. doi: 10.1016/j.urolonc.2017.09.026. Epub 2017 Nov 16.

PMID:
29153942
7.

Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.

Keefe DT, Schieda N, El Hallani S, Breau RH, Morash C, Robertson SJ, Mai KT, Belanger EC, Flood TA.

Virchows Arch. 2015 Oct;467(4):437-42. doi: 10.1007/s00428-015-1809-5. Epub 2015 Jul 31.

PMID:
26229020
8.

Postoperative upgrading of prostate cancer in men ≥75 years: a propensity score-matched analysis.

Herlemann A, Buchner A, Kretschmer A, Apfelbeck M, Stief CG, Gratzke C, Tritschler S.

World J Urol. 2017 Oct;35(10):1517-1524. doi: 10.1007/s00345-017-2045-1. Epub 2017 May 10.

PMID:
28493044
9.

Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.

Flood TA, Schieda N, Keefe DT, Breau RH, Morash C, Hogan K, Belanger EC, Mai KT, Robertson SJ.

Virchows Arch. 2016 Sep;469(3):313-9. doi: 10.1007/s00428-016-1981-2. Epub 2016 Jul 10.

PMID:
27394432
10.

Incidence of upgrading and upstaging in patients with low-volume Gleason score 3+4 prostate cancers at biopsy: finding a new group eligible for active surveillance.

Park HJ, Ha YS, Park SY, Kim YT, Lee TY, Kim JH, Lee DH, Kim WJ, Kim IY.

Urol Int. 2013;90(3):301-5. doi: 10.1159/000345292. Epub 2013 Feb 5.

PMID:
23391718
11.

Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.

Bhindi B, Locke J, Alibhai SMH, Kulkarni GS, Margel DS, Hamilton RJ, Finelli A, Trachtenberg J, Zlotta AR, Toi A, Hersey KM, Evans A, van der Kwast TH, Fleshner NE.

Eur Urol. 2015 Jan;67(1):64-70. doi: 10.1016/j.eururo.2014.01.040. Epub 2014 Feb 14.

PMID:
24568896
12.

Upgrading and upstaging of low-risk prostate cancer among Korean patients: a multicenter study.

Hwang I, Lim D, Jeong YB, Park SC, Noh JH, Kwon DD, Kang TW.

Asian J Androl. 2015 Sep-Oct;17(5):811-4. doi: 10.4103/1008-682X.143751.

13.

Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.

Oh JJ, Hong SK, Lee JK, Lee BK, Lee S, Kwon OS, Byun SS, Lee SE.

BJU Int. 2012 Dec;110(11 Pt B):E494-9. doi: 10.1111/j.1464-410X.2012.11182.x. Epub 2012 Apr 30.

14.

Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy.

Bhindi B, Xie WY, Kulkarni GS, Hamilton RJ, Nesbitt M, Finelli A, Zlotta AR, Evans A, van der Kwast TH, Alibhai SM, Trachtenberg J, Fleshner NE.

Urology. 2016 Jul;93:77-85. doi: 10.1016/j.urology.2016.01.041. Epub 2016 Mar 22.

PMID:
27015944
15.

The metabolic syndrome is associated with more aggressive prostate cancer.

Ozbek E, Otunctemur A, Dursun M, Sahin S, Besiroglu H, Koklu I, Erkoc M, Danis E, Bozkurt M.

Asian Pac J Cancer Prev. 2014;15(9):4029-32.

16.

Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.

Faisal FA, Sundi D, Pierorazio PM, Ball MW, Humphreys EB, Han M, Epstein JI, Partin AW, Carter HB, Bivalacqua TJ, Schaeffer EM, Ross AE.

BJU Int. 2014 Dec;114(6b):E120-E129. doi: 10.1111/bju.12771. Epub 2014 Aug 13.

17.

Multiparametric magnetic resonance imaging and frozen-section analysis efficiently predict upgrading, upstaging, and extraprostatic extension in patients undergoing nerve-sparing robotic-assisted radical prostatectomy.

Bianchi R, Cozzi G, Petralia G, Alessi S, Renne G, Bottero D, Brescia A, Cioffi A, Cordima G, Ferro M, Matei DV, Mazzoleni F, Musi G, Mistretta FA, Serino A, Tringali VM, Coman I, De Cobelli O.

Medicine (Baltimore). 2016 Oct;95(40):e4519.

18.

Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.

Tilki D, Schlenker B, John M, Buchner A, Stanislaus P, Gratzke C, Karl A, Tan GY, Ergün S, Tewari AK, Stief CG, Seitz M, Reich O.

Urol Oncol. 2011 Sep-Oct;29(5):508-14. doi: 10.1016/j.urolonc.2009.07.003. Epub 2009 Oct 17.

PMID:
19837614
19.

Is transperineal prostate biopsy more accurate than transrectal biopsy in determining final Gleason score and clinical risk category? A comparative analysis.

Scott S, Samaratunga H, Chabert C, Breckenridge M, Gianduzzo T.

BJU Int. 2015 Oct;116 Suppl 3:26-30. doi: 10.1111/bju.13165. Epub 2015 Aug 11.

20.

Comparison of pathological and biochemical outcomes after radical prostatectomy in Korean patients with serum PSA ranges.

Lee HW, Jeon HG, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM.

J Korean Med Sci. 2015 Mar;30(3):317-22. doi: 10.3346/jkms.2015.30.3.317. Epub 2015 Feb 16.

Supplemental Content

Support Center